Nationale-Nederlanden Powszechne Towarzystwo Emerytalne’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Nationale-Nederlanden Powszechne Towarzystwo Emerytalne’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-380,423	Closed	-$31.8M	–	63
2024 Q4	$31.8M	Sell	380,423 -24,233	-6%	-$1.99M	3.84%	7
2024 Q3	$29.6M	Buy	+404,656	New	+$30.4M	4.11%	6

Other funds holding ITCI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Nationale-Nederlanden Powszechne Towarzystwo Emerytalne's ITCI Position: Q1 2025 in Review

Nationale-Nederlanden Powszechne Towarzystwo Emerytalne sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2025, closing a stake of 380,423 shares — an estimated $31.8M sold.

Nationale-Nederlanden Powszechne Towarzystwo Emerytalne first reported a position in ITCI in Q3 2024 and held it in 2 quarters. The position peaked at $31.8M in Q4 2024. 395 funds tracked by Wall St. Rank hold ITCI as of Q1 2025.

Nationale-Nederlanden Powszechne Towarzystwo Emerytalne reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2025 after selling out during the quarter.
Nationale-Nederlanden Powszechne Towarzystwo Emerytalne sold 380,423 Intra-Cellular Therapies Inc. shares in Q1 2025, an estimated $31.8M.
Nationale-Nederlanden Powszechne Towarzystwo Emerytalne first reported a position in Intra-Cellular Therapies Inc. in Q3 2024 and held it in 2 quarters.
Nationale-Nederlanden Powszechne Towarzystwo Emerytalne's Intra-Cellular Therapies Inc. position peaked at $31.8M in Q4 2024.
395 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2025.

Based on Nationale-Nederlanden Powszechne Towarzystwo Emerytalne's 13F filing for Q1 2025, filed 6 May 2025.